A phase III trial of capivasertib and abiraterone versus placebo and abiraterone in patients with de novo metastatic hormone-sensitive prostate cancer characterized by PTEN deficiency (CAPItello-281).

Presenter

Karim Fizazi, MD, PhD

Institut Gustave Roussy and University of Paris Sud

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Videos & Slides

ondemand_video

Videos & Slides

2024 ASCO Annual Meeting

bookmark_border

play_arrow

Post-progression survival of patients with metastatic hormone-sensitive prostate cancer (mHSPC) who received darolutamide or placebo: Post hoc analysis of ARASENS.

Speaker: Marc-Oliver Grimm, MD

ondemand_video

Videos & Slides

2024 ASCO Genitourinary Cancers Symposium

bookmark_border

play_arrow

Efficacy of olaparib (O) plus abiraterone (A) versus placebo (P) plus A in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with single homologous recombination repair gene mutations (HRRm) in the PROpel trial.

Speaker: Neal D. Shore, MD, FACS

ondemand_video

Videos & Slides

2023 ASCO Annual Meeting

bookmark_border

play_arrow

Health-related quality of life (HRQoL) and pain outcomes for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone (abi) and olaparib (ola) versus (vs) abi and placebo (pbo) in the phase III PROpel trial.

Speaker: Andrew J. Armstrong, MD

ondemand_video

Videos & Slides

2023 ASCO Genitourinary Cancers Symposium

bookmark_border

play_arrow

Final overall survival (OS) in PROpel: abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC).

Speaker: Noel Clarke, FRCS